Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While PEG-MGF is used experimentally to enhance muscle repair and hypertrophy after mechanical overload or injury by stimulating satellite-cell activation and protein synthesis6373138, Semaglutide is approved for type 2 diabetes and chronic weight management, significantly lowering HbA1c and body weight by modulating incretin pathways232480.
While PEG-MGF works as a poly(ethylene glycol)-conjugated form of Mechano Growth Factor (IGF-1Ec splice variant) comprising the 24-aa C-terminal E-peptide of IGF-1, designed to extend half-life while activating IGF-1 receptor–mediated anabolic signaling in muscle satellite cells637322138, Semaglutide is a modified GLP-1(7–37) analog with three key changes—Ala8→Aib, Lys26 acylated with a C18 fatty diacid, and Lys34→Arg—resulting in a long-acting GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite23647480.
PEG-MGF
IGF1
Semaglutide
GCG
PEG-MGF and Semaglutide are noticeably different, with limited direct overlap in their usual biological context. Both are often discussed in Cardiovascular health contexts, while PEG-MGF is more of a signal peptide and Semaglutide is better described as a metabolic peptide and Hormone peptide. Their biological logic is quite different: PEG-MGF is a growth factor mimetic and a signaling modulator, whereas Semaglutide is a receptor agonist and a hormone analog. Both are synthetic in origin and their development context also differs, with PEG-MGF in Preclinical development while Semaglutide is approved. PEG-MGF carries pegylation features, while Semaglutide instead reflects lipidation changes, while their sequence patterns also diverge, with PEG-MGF showing protein-mimetic sequence features and Semaglutide showing alpha-helical domain features.